Table 3 Pooled summary estimates derived from direct and network meta-analyses on the comparative efficacy of prophylaxis antifungal agents against IFIs
Comparisons | Direct estimate, OR (95% CI) | Network meta-analysis, OR (95% CrI) |
|---|---|---|
Compared with fluconazole | ||
 Itraconazole | 0.71 (0.44–1.15) | 0.78 (0.50–1.15) |
 Posaconazole | 0.32 (0.16–0.62) | 0.30 (0.12–0.60) |
 Voriconazole | 0.93 (0.53–1.62) | 0.73 (0.31–1.38) |
 Amphotericin B | 0.96 (0.33–2.83) | 1.28 (0.71–2.04) |
 Caspofungin | 0.36 (0.14–0.89) | 0.56 (0.20–1.27) |
 Micafungin | 0.88 (0.36–2.16) | 0.84 (0.25–2.11) |
 Placebo | 2.20 (1.42–3.42) | 2.19 (1.39–3.16) |
Compared with itraconazole | ||
 Posaconazole | 0.21 (0.08–0.62) | 0.40 (0.15–0.85) |
 Voriconazole | 0.48 (0.13–1.72) | 0.98 (0.40–1.92) |
 Amphotericin B | 1.78 (0.76–4.18) | 1.70 (0.86–2.85) |
 Caspofungin | 1.14 (0.37–3.45) | 0.74 (0.26–1.68) |
 Micafungin | – | 1.13 (0.31–2.92) |
 Placebo | 1.77 (0.83–3.76) | 2.92 (1.64–4.63) |
Compared with posaconazole | ||
 Voriconazole | – | 2.85 (0.83–7.08) |
 Amphotericin B | 3.30 (0.14–76.46)) | 4.97 (1.73–11.35) |
 Caspofungin | – | 2.20 (0.55–6.24) |
 Micafungin | 1.58 (0.40–6.30) | 3.13 (0.85–8.32) |
 Placebo | – | 8.51 (3.25–18.72) |
Compared with voriconazole | ||
 Amphotericin B | 1.40 (0.35–5.52) | 1.96 (0.80–4.06) |
 Caspofungin | – | 0.87 (0.23–2.41) |
 Micafungin | – | 1.32 (0.30–4.01) |
 Placebo | – | 3.40 (1.41–7.14) |
Compared with amphotericin B | ||
 Caspofungin | – | 0.47 (0.14–1.20) |
 Micafungin | – | 0.71 (0.19–1.95) |
 Placebo | 1.11 (0.66–1.87) | 1.80 (1.04–2.95) |
Compared with caspofungin | ||
 Micafungin | – | 1.88 (0.35–5.81) |
 Placebo | – | 4.85 (1.54–11.27) |
Compared with micafungin | ||
 Placebo | – | 3.46 (0.95–9.06) |